Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinica BavieraXMAD:CBAV +0.35%100 EV-to-EBITDA is 10.41 as of Jul. 25, 2026, which is 38% above its 10-year median of 7.54. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.50 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 65.81% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clinica Baviera's enterprise value is €921.3 Mil.
Clinica Baviera's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €88.5 Mil. Therefore, Clinica Baviera's EV-to-EBITDA for today is 10.41.
The historical rank and industry rank for Clinica Baviera's EV-to-EBITDA or its related term are showing as below:
XMAD:CBAV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.85 Med: 7.54 Max: 12.06
Current: 10.41
During the past 13 years, the highest EV-to-EBITDA of Clinica Baviera was 12.06. The lowest was 3.85. And the median was 7.54.
XMAD:CBAV's EV-to-EBITDA is ranked better than 65.81% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.61
vs XMAD:CBAV: 10.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clinica Baviera's PE Ratio (TTM) for today is calculated as:
Clinica Baviera's share price for today is €57.20.
Clinica Baviera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.739.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Clinica Baviera's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:CBAV vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's EV-to-EBITDA falls into.
Clinica Baviera's current Enterprise Value is €921.3 Mil.
Clinica Baviera's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €88.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera (XMAD:CBAV) has a EV-to-EBITDA of 10.41 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clinica Baviera. This is 38% above median its historical median of 7.54. Over the past decade, Clinica Baviera's EV-to-EBITDA has ranged from 3.85 to 12.06. According to the industry distribution chart, Clinica Baviera ranks #40 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 34.2%.
Is Clinica Baviera's EV-to-EBITDA too high?
Clinica Baviera's current EV-to-EBITDA of 10.41 is 38% above median its 10-year median of 7.54. Over the past 10 years, this metric has ranged from a low of 3.85 to a high of 12.06. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.61. Clinica Baviera's value of 10.41 is 28.7% below this industry median. Based on the distribution chart, Clinica Baviera ranks #40 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #40 out of 117 companies for EV-to-EBITDA. This puts Clinica Baviera in the upper half of its industry. The industry median EV-to-EBITDA is 14.61. Clinica Baviera's value of 10.41 is 28.7% below this benchmark. Historically, Clinica Baviera's own EV-to-EBITDA has ranged from 3.85 to 12.06 over the past decade. While the company's 10-year median is 7.54 vs. the industry median of 14.61, Clinica Baviera has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.61, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current EV-to-EBITDA of 10.41 is 28.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clinica Baviera. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current EV-to-EBITDA is 10.41, which is 38% above median its own 10-year median of 7.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.50, compared to a current price of €57.20 — trading 37.8% above its estimated fair value. The current EV-to-EBITDA is 10.41, which is 38% above median its 10-year median of 7.54 and 28.7% below the Medical Diagnostics & Research industry median of 14.61. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current EV-to-EBITDA is 10.41 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €57.20 is trading 37.8% above its estimated GF Value™ of €41.50.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
EV-to-EBITDA: 10.41 (38% above median its 10-year median of 7.54)
GF Value™: €41.50 vs. price of €57.20 (37.8% above fair value)
Industry Position: 28.7% below the Medical Diagnostics & Research median (#40 of 117)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
